CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for PhaseBio Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

PhaseBio Pharmaceuticals Inc
1 Great Valley Pkwy Ste 30
Phone: (610) 981-6500p:610 981-6500 MALVERN, PA  19355-1423  United States Fax: (302) 531-3150f:302 531-3150
This company's Plan of Liquidation went into effect on 9/30/2024
This company ceased filing statements with the SEC on 9/30/2024.
This entity represents the bankrupt estate of the former businesses (assets) of PhaseBio Pharmaceuticals, Inc. that were not sold to SFJ Pharmaceuticals, Inc. on 1/13/2023.
This company is no longer actively traded on any major stock exchange.
Business Summary
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapies for cardiovascular diseases. Its lead product candidate, bentracimab (also known as PB2452), is a novel reversal agent for the antiplatelet drug ticagrelor. Ticagrelor is an antiplatelet therapy widely prescribed to reduce the rates of death, heart attack and stroke in patients with acute coronary syndrome (ACS), or who have previously experienced a heart attack. Ticagrelor binds to platelets to prevent them from forming blood clots that could restrict blood flow. The Company is also developing its preclinical product candidate, PB6440, an oral selective aldosterone synthase inhibitor for treatment-resistant hypertension. The Company is leveraging ELP biopolymer technology to evaluate additional preclinical and discovery-stage candidates. Its focus is on proteins and peptides that are scientifically or clinically validated.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202212/31/2021YesYesYes-Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board, Co-Founder Clay B.Thorp 53 11/1/2014 1/1/2002
Chief Executive Officer, Director Jonathan P.Mow 58 9/1/2014 9/1/2014
Principal Financial Officer Lawrence R.Perkins 45 11/30/2022 11/30/2022
10 additional Officers and Directors records available in full report.

Business Names
Business Name
2K4
PHAS
PHASQ

General Information
Outstanding Shares: 49,858,116 (As of 8/8/2022)
Shareholders: 50
Stock Exchange: OTC
Federal Tax Id: 030375697
Fax Number: (302) 531-3150


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024